Among RB1-wild-type patients, those treated with a NSCLC regimen (platinum plus gemcitabine or paclitaxel) had significantly better PFS and OS compared with those treated with a SCLC regimen (platinum plus etoposide): PFS was 6.1 vs 5.7 months (P = 0.019) and OS was 9.6 vs 5.8 months (P = 0.026). This evidence concerns the gene RB1 and non-small cell lung carcinoma.